Cargando…
Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO
Direct at line monitoring of live virus particles in commercial manufacturing of vaccines is challenging due to their small size. Detection of malformed or damaged virions with reduced potency is rate-limited by release potency assays with long turnaround times. Thus, preempting batch failures cause...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016999/ https://www.ncbi.nlm.nih.gov/pubmed/33795759 http://dx.doi.org/10.1038/s41598-021-86688-z |
_version_ | 1783673973773434880 |
---|---|
author | Ricci, Geoffri Minsker, Kevin Kapish, Austin Osborn, James Ha, Sha Davide, Joseph Califano, Joseph P. Sehlin, Darrell Rustandi, Richard R. Dick, Lawrence W. Vlasak, Josef Culp, Timothy D. Baudy, Andreas Bell, Edward Mukherjee, Malini |
author_facet | Ricci, Geoffri Minsker, Kevin Kapish, Austin Osborn, James Ha, Sha Davide, Joseph Califano, Joseph P. Sehlin, Darrell Rustandi, Richard R. Dick, Lawrence W. Vlasak, Josef Culp, Timothy D. Baudy, Andreas Bell, Edward Mukherjee, Malini |
author_sort | Ricci, Geoffri |
collection | PubMed |
description | Direct at line monitoring of live virus particles in commercial manufacturing of vaccines is challenging due to their small size. Detection of malformed or damaged virions with reduced potency is rate-limited by release potency assays with long turnaround times. Thus, preempting batch failures caused by out of specification potency results is almost impossible. Much needed are in-process tools that can monitor and detect compromised viral particles in live-virus vaccines (LVVs) manufacturing based on changes in their biophysical properties to provide timely measures to rectify process stresses leading to such damage. Using ERVEBO, MSD’s Ebola virus vaccine as an example, here we describe a flow virometry assay that can quickly detect damaged virus particles and provide mechanistic insight into process parameters contributing to the damage. Furthermore, we describe a 24-h high throughput infectivity assay that can be used to correlate damaged particles directly to loss in viral infectivity (potency) in-process. Collectively, we provide a set of innovative tools to enable rapid process development, process monitoring, and control strategy implementation in large scale LVV manufacturing. |
format | Online Article Text |
id | pubmed-8016999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80169992021-04-07 Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO Ricci, Geoffri Minsker, Kevin Kapish, Austin Osborn, James Ha, Sha Davide, Joseph Califano, Joseph P. Sehlin, Darrell Rustandi, Richard R. Dick, Lawrence W. Vlasak, Josef Culp, Timothy D. Baudy, Andreas Bell, Edward Mukherjee, Malini Sci Rep Article Direct at line monitoring of live virus particles in commercial manufacturing of vaccines is challenging due to their small size. Detection of malformed or damaged virions with reduced potency is rate-limited by release potency assays with long turnaround times. Thus, preempting batch failures caused by out of specification potency results is almost impossible. Much needed are in-process tools that can monitor and detect compromised viral particles in live-virus vaccines (LVVs) manufacturing based on changes in their biophysical properties to provide timely measures to rectify process stresses leading to such damage. Using ERVEBO, MSD’s Ebola virus vaccine as an example, here we describe a flow virometry assay that can quickly detect damaged virus particles and provide mechanistic insight into process parameters contributing to the damage. Furthermore, we describe a 24-h high throughput infectivity assay that can be used to correlate damaged particles directly to loss in viral infectivity (potency) in-process. Collectively, we provide a set of innovative tools to enable rapid process development, process monitoring, and control strategy implementation in large scale LVV manufacturing. Nature Publishing Group UK 2021-04-01 /pmc/articles/PMC8016999/ /pubmed/33795759 http://dx.doi.org/10.1038/s41598-021-86688-z Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Ricci, Geoffri Minsker, Kevin Kapish, Austin Osborn, James Ha, Sha Davide, Joseph Califano, Joseph P. Sehlin, Darrell Rustandi, Richard R. Dick, Lawrence W. Vlasak, Josef Culp, Timothy D. Baudy, Andreas Bell, Edward Mukherjee, Malini Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO |
title | Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO |
title_full | Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO |
title_fullStr | Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO |
title_full_unstemmed | Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO |
title_short | Flow virometry for process monitoring of live virus vaccines-lessons learned from ERVEBO |
title_sort | flow virometry for process monitoring of live virus vaccines-lessons learned from ervebo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016999/ https://www.ncbi.nlm.nih.gov/pubmed/33795759 http://dx.doi.org/10.1038/s41598-021-86688-z |
work_keys_str_mv | AT riccigeoffri flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT minskerkevin flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT kapishaustin flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT osbornjames flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT hasha flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT davidejoseph flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT califanojosephp flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT sehlindarrell flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT rustandirichardr flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT dicklawrencew flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT vlasakjosef flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT culptimothyd flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT baudyandreas flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT belledward flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo AT mukherjeemalini flowvirometryforprocessmonitoringoflivevirusvaccineslessonslearnedfromervebo |